$95.5 K

ECTE Mkt cap, 05-Oct-2018
Echo Therapeutics Net income (Q3, 2016)794.2 K
Echo Therapeutics EBIT (Q3, 2016)-1.8 M
Echo Therapeutics Cash, 30-Sep-2016172.7 K

Echo Therapeutics Income Statement

Annual

USDFY, 2013FY, 2015

Revenue

27.6k

R&D expense

11.3m2.8m

General and administrative expense

8.4m4.3m

Operating expense total

19.7m17.5m

Depreciation and amortization

521.9k

EBIT

(19.6m)(17.5m)

EBIT margin, %

(71147%)

Interest expense

3.9m15.3k

Interest income

3.1k

Net Income

(19.1m)(22.2m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q3, 2016

Revenue

22.6k19.1k19.1k19.1k

R&D expense

2.8m1.1m1.7m1.2m797.8k640.6k588.6k

General and administrative expense

2.2m1.5m2.2m1.7m1.4m739.1k1.2m

Operating expense total

4.9m2.7m3.9m2.9m12.3m1.5m1.8m

Depreciation and amortization

361.6k39.2k26.9k

EBIT

(4.9m)(2.7m)(3.9m)(2.9m)(12.3m)(1.5m)(1.8m)

EBIT margin, %

(21837%)(13975%)(20492%)(15248%)

Interest expense

242.1k243.2k243.8k3.1m2.0k212.0133.1k

Interest income

877.0356.0835.0181.0

Net Income

(5.2m)(2.8m)(3.8m)(5.5m)(10.8m)(1.8m)794.2k

Echo Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015

Cash

8.1m1.3m56.2k

Inventories

49.2k490.8k

Current Assets

9.4m1.8m300.7k

PP&E

1.1m267.7k

Total Assets

23.1m12.6m805.1k

Accounts Payable

1.0m1.8m2.2m

Current Liabilities

3.6m3.0m3.2m

Total Debt

Total Liabilities

3.7m3.3m

Additional Paid-in Capital

132.2m137.3m147.4m

Retained Earnings

(113.0m)(127.9m)(150.1m)

Total Equity

19.4m9.5m(2.5m)

Financial Leverage

1.2 x1.3 x-0.3 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q3, 2016

Cash

6.1m7.1m4.1m1.5m337.4k3.2k172.7k

Current Assets

7.8m8.2m5.3m1.8m680.4k226.7k402.0k

PP&E

443.4k302.0k188.9k

Total Assets

21.9m21.6m18.4m12.6m1.3m765.4k1.1m

Accounts Payable

1.6m704.2k1.0m905.6k1.5m1.9m1.9m

Short-term debt

2.6m

Current Liabilities

4.2m2.6m2.6m1.9m2.8m2.5m7.3m

Long-term debt

57.3k

Total Debt

2.7m

Total Liabilities

4.2m2.6m2.6m1.9m2.9m2.6m7.4m

Additional Paid-in Capital

127.0m133.0m135.1m135.6m145.3m147.1m148.4m

Retained Earnings

(109.5m)(115.7m)(119.5m)(125.0m)(147.1m)(148.9m)(154.9m)

Total Equity

17.6m18.9m15.8m10.7m(6.3m)

Financial Leverage

1.2 x1.1 x1.2 x1.2 x-0.2 x

Echo Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015

Net Income

(19.1m)(15.0m)(22.2m)

Depreciation and Amortization

391.6k392.7k521.9k

Accounts Receivable

Inventories

26.4k(441.6k)

Accounts Payable

(1.3m)765.1k656.6k

Cash From Operating Activities

(19.4m)(10.7m)(5.1m)

Purchases of PP&E

(36.6k)(55.8k)

Cash From Investing Activities

(144.0k)215.4k(113.7k)

Cash From Financing Activities

23.9m3.7m4.0m

Interest Paid

275.02.2k15.5k

Income Taxes Paid

4.1k

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q3, 2016

Net Income

(15.6m)(2.8m)(6.5m)(12.0m)(19.1m)(20.9m)(4.8m)

Depreciation and Amortization

288.9k99.9k198.8k296.7k448.3k487.5k85.1k

Accounts Payable

(768.1k)(332.1k)(4.0k)(130.7k)(5.5k)396.0k(152.2k)

Cash From Operating Activities

(16.2m)(3.2m)(6.5m)(9.1m)(3.2m)(4.2m)(4.2m)

Purchases of PP&E

(12.2k)(55.8k)(6.4k)

Cash From Investing Activities

(487.4k)250.0k219.0k215.3k(119.6k)(113.7k)

Cash From Financing Activities

19.0m2.0m2.3m2.3m2.3m3.0m4.5m

Interest Paid

114.1k1.2k3.1k2.2k4.8k5.0k15.7k

Income Taxes Paid

2.8k

Echo Therapeutics Ratios

USDY, 2016

Financial Leverage

-0.2 x